Online citations, reference lists, and bibliographies.
← Back to Search

Osteopontin Is Not A Specific Marker In Malignant Pleural Mesothelioma

L. Paleari, N. Rotolo, A. Imperatori, R. Puzone, F. Sessa, Francesca Franzi, E. Meacci, P. Camplese, A. Cesario, M. Paganuzzi
Published 2009 ·

Cite This
Download PDF
Analyze on Scholarcy
Share
Background and aims: osteopontin (oPn) is an integrin-binding protein recently shown to be related to tumorigenesis, progression and metastasis in different experimental models of malignancy. malignant pleural mesothelioma (mPm) is a fatal disease in which the prognosis remains very poor and the knowledge of predictive factors for outcome is insufficient. the identification of new molecules involved in cancer initiation and development is a fundamental step for improving the curability of this kind of tumor. the purpose of this study is to define the role of oPn in the diagnosis of mPm by determining its prognostic and diagnostic value. methods: a group of 24 surgically staged mPm subjects was compared with a group of 31 subjects with nonmalignant pulmonary diseases, and with 37 healthy controls. tumor tissue was analyzed for oPn by immunohistochemical tests, and plasma oPn levels were measured by an enzyme-linked immunosorbent assay. results: Plasma oPn levels were not significantly higher in either of the patient groups compared with the control group. immunohistochemical analysis revealed oPn staining of tumor cells in 21 of 24 mPms. receiver operating characteristic curve/area under the curve (roc/auc) analysis comparing the plasma oPn levels in the healthy group with those of mPm patients showed 40% sensitivity and 100% specificity at a cutoff value of 60.8 ng of oPn per milliliter (auc 0.6). conclusion: Plasma oPn levels do not discriminate between chronic inflammatory and malignant lung diseases and staining intensity in mPm specimens does not correlate with oPn plasma levels. (int J Biol markers 2009; 24: 112-7)
This paper references
10.1016/j.lungcan.2008.06.020
Osteopontin is involved in the formation of malignant pleural effusion in lung cancer.
R. Cui (2009)
Osteopontin: possible role in prostate cancer progression.
G. Thalmann (1999)
osteopontin is dependent on thrombin anion-binding exosites
CC Kazanecki (2008)
10.1016/S0304-3835(01)00607-3
Differential osteopontin expression in lung cancer.
J. Zhang (2001)
diagnostic biomarker for ovarian cancer
T Ue (2002)
mesothelioma, and serum osteopontin levels
NS Fedarko (2005)
pleural mesothelioma: current status
S Cappia (2008)
epithelioid; s, sarcomatoid Gender Diagnosis oPn immunohistochemistry score oPn plasma level (ng/mL) Paleari et al 117 factor and osteopontin in tumour biology
E “Diagnosis (2000)
10.1073/pnas.0801414105
Development of pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1
R. Eferl (2008)
inflammation and biomineralization
DT Denhardt (2000)
10.1016/S0945-053X(00)00108-6
Osteopontin: a versatile regulator of inflammation and biomineralization.
C. Giachelli (2000)
Elevated bone 19 . sialoprotein and osteopontin in colon , breast , prostate , and lung cancer
T Yuan (2001)
10.1023/A:1014734930781
The Role of Osteopontin in Breast Cancer: Clinical and Experimental Studies
A. Tuck (2004)
a possible anchor of osteoclast to bone
CM Giacchelli (1990)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
cancer: clinical and experimental studies
GN Thalmann (2001)
sialoprotein and osteopontin in colon, breast, prostate, and lung cancer
Z Hu (2001)
Co - expression of 11 . osteopontin and CD 44 v 9 in gastric cancer
T Ue (1998)
10.5301/JBM.2008.3906
Osteopontin expression according to molecular profile of invasive breast cancer: a clinicopathological and immunohistochemical study.
A. Ribeiro-Silva (2008)
emerging therapeutic target for anticancer therapy
L Greillier (2007)
Vascular endothelial growth factor and osteopontin in tumor biology.
N. Shijubo (2000)
10.1002/jcb.21558
Control of osteopontin signaling and function by post‐translational phosphorylation and protein folding
C. Kazanecki (2007)
Cancer research. Inflammation and cancer: the link grows stronger.
J. Marx (2004)
10.1309/TWCQV536WWRNEU51
Prognostic role of osteopontin expression in malignant pleural mesothelioma.
S. Cappia (2008)
10.1093/JNCI/94.7.513
Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling.
D. Agrawal (2002)
osteopontin in metastatic breast cancer associated with increased tumour burden and decreased survival
J Koopmann (1997)
10.1016/S0016-5085(03)82230-8
Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.
J. Koopmann (2004)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
osteopontin as biomarker for pancreatic adenocarcinoma
A Ribeiro-Silva (2004)
osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment
S Jain (2007)
10.1517/14728222.11.1.81
Osteopontin: an emerging therapeutic target for anticancer therapy
S. Jain (2007)
expression in lung cancer
H Singhal (2001)
10.1097/JTO.0b013e318180477b
Comparison of Osteopontin, Megakaryocyte Potentiating Factor, and Mesothelin Proteins as Markers in the Serum of Patients with Malignant Mesothelioma
J. Creaney (2008)
10.1126/SCIENCE.306.5698.966
Inflammation and Cancer: The Link Grows Stronger
J. Marx (2004)
10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V
Co‐expression of osteopontin and CD44v9 in gastric cancer
T. Ue (1998)
a means to cope with environmental insults: regulation of inflammation, tissue remodelling, and cell survival
LM Coussens (2001)
10.1001/JAMA.287.13.1671
Osteopontin as a potential diagnostic biomarker for ovarian cancer.
J. Kim (2002)
osteopontin signaling and function by post-translational phosphorylation and protein folding
F Montanaro (2007)
10.2165/1250444-200812060-00004
Biomarkers for malignant pleural mesothelioma: current status.
L. Greillier (2008)
10.1172/JCI12980
Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival.
D. Denhardt (2001)
10.1074/jbc.M708629200
Thrombin Hydrolysis of Human Osteopontin Is Dependent on Thrombin Anion-binding Exosites*
Timothy Myles (2008)
pulmonary fibrosis through a pathway involving the transcription factor Fra-2/AP-1
T Myles (2008)
lead marker of colon cancer progression, using pooled sample expression profile
JH Kim (2002)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival.
H. Singhal (1997)
Osteopontin . Crit Rev Oral 1
FP Reinhold
in the formation of malignant pleural effusion in lung cancer
R Eferl (2009)
osteopontin expression in malignant pleural mesothelioma
R Cui (2008)
possible role in prostate cancer progression
D Agrawal (1999)
Osteopontin ñ 2 . a possible anchor of osteoclast to bone
CM Giacchelli (1990)
10.1016/0169-5002(95)00595-1
Osteopontin expression in lung cancer.
A. Chambers (1996)



Semantic Scholar Logo Some data provided by SemanticScholar